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Clostridium difficile-associated diarrhoea (CDAD), also known as C. difficile infection (CDI), is the leading cause of infectious nosocomial gastrointestinal illness.
1,2
Steadily increasing CDI rates in US hospitals, 1 emergence of epidemic and hypervirulent strains (e.g. BI/NAP1/027), 3 increased incidences of community acquired CDI 4 and enormous costs to healthcare systems (estimated at $3.2 billion/year in the US alone) 5 have focused considerable attention on this disease over the past decade. 6, 7 C. difficile is a Gram-positive, rod-shaped, spore-forming anaerobe transmitted via the oralfecal route. In its vegetative form it is highly sensitive to oxygen but its spores are heat stable, insensitive to standard disinfectants, able to survive for long periods in the environment and they can passage intact through the acidic stomach. C. difficile typically resides asymptomatically in the human gastrointestinal tract until normal microflora are disrupted, such as following broad-spectrum antibiotic treatments, after which it can overgrow producing three toxins; toxin A (TcdA), toxin B (TcdB) and the binary toxin CDT.. Ensuing CDI can range in severity from mild diarrhoea to life-threatening pseudomembranous colitis (PMC) and toxic megacolon. 6 Treatments for CDI historically have involved antibiotic withdrawal followed by oral metronidazole 1 (500 mg t.i.d, 10-14 days) or vancomycin 2 (125-250 mg q.i.d, 10 days) but treatment failure remains as a significant and increasing problem (reportedly > 35% for metronidazole and 1-16% for vancomycin).
2
For patients who develop severe CDI (diarrhoea with leucocytosis, PMC or toxic shock) metronidazole is effective in 76% of cases and vancomycin 97%. A major risk factor for recurrent CDI is failure to re-establish normal protective gut microflora due to the action of metronidazole and vancomycin on gut commensals and the ineffectiveness of these antibiotics against C. difficile spores. Optimer Pharmaceuticals Inc.), 9 an oral macrocyclic narrow-spectrum antibiotic developed specifically for CDI. Fidaxomicin shows very high in vitro potency against C. difficile (minimum inhibitory concentrations (MICs) against clinical isolates 0.008-0.25 mg/L) and reduced activity against gut commensals, in particular Bacteroides species. 10 This and lower post-treatment C. difficile spore counts 10 are thought to contribute to reduced CDI recurrence with fidaxomicin. 11, 12 Relapse rates for infections caused by the BI/NAP1/027 hypervirulent strain, however, are the same for vancomycin and fidaxomicin 13, 14 and many hospitals have been slow to embrace the new drug due to its high cost (> US$2700 per treatment, c.f. metronidazole US$22 and vancomycin $1270). 15 While the proper place for fidaxomicin in clinical practice is still being established the search continues for alternative and, ideally, more cost-effective agents. Attractive new compound classes would include those that show high selectivity for C. difficile over gut commensals along with activity against the stationary-phase cells responsible for spore formation. 16 In a recent high-throughput screening (HTS) and counter-screening campaign we identified that certain diarylacylhydrazones are clostridium-selective agents. 17 This paper reports the activity and selectivity of diaryacylhydrazone screening hits, describes structure-activity studies around the class and reports that a representative member is active against stationary-phase C. difficile cells. Evidence is presented that selective antiClostridium activity in the class may arise, in part, through a protonophoric mechanism. High-throughput screening was carried out to identify hits against C. difficile CD196. Clostridium perfringens was included to identify species-specific anti-C. difficile compounds.
Four acylhydrazones carrying aryl substituents at R against CD196 were equivalent to their MICs, confirming that the compounds are bactericidal.
Quinolinium acetate, chloride and mesylate salts of 7 showed identical activity to the free base 7.
Compound 4 was shown to have activity similar to vancomycin (< 2-fold difference in MIC) against five C. difficile clinical isolates (Supporting Information, Figure S1 ). The MIC of 8 against CD196 was found to be 6.25 g/mL and it showed higher potency against C. perfringens (MIC ≤ 0.78 g/mL). The compound's selectivity for Clostridium species over gut commensals was similar to 5 showing only weak activity against B. fragilis and B. thetaiotaomicron (MIC = 12.5 g/mL) and no other activity across the panel. It was noted that diarylacylhydrazones structurally resemble nitrofurans, an older class of broad spectrum antibiotics that have seen widespread historical use in humans and in veterinary medicine. 
Demonstrating that nitrofurans invoke different antibacterial mechanisms and that anti-
Clostridium activity is lost in diarylacylhydrazones upon methylation of the 'amide' nitrogen and/or the ortho-phenolic group present at R 2 led to speculation that the compounds might be exerting their selective effects through a protonophoric mechanism. To test this hypothesis, MIC measurements were obtained with three well-known membrane-active protonophores; carbonyl cyanide mchlorophenylhydrazone (CCCP), 20 pentachlorophenol (PCP), 21 and 2,4-dinitrophenol (2,4-DNP) 22 ( Figure 4 ) against CD196 and the gut panel. It was reasoned that if Clostridium-selective activity were observed with one or more of these it would support a protonophoric mechanism for diarylacylhydrazones. CCCP was found to be highly active against CD196 (MIC = 1.56 g/mL) and also showed high selectivity, affecting only one other panel member (B. longum, MIC = 3.25 g/mL).
In contrast to diarylacylhydrazones, CCCP showed no activity against C. perfringens. PCP and 2,4-DNP showed only weak activity across the panel and no selectivity towards Clostridium, indicating that selective action against Clostridium is not a general effect of protonophores. The similarity between the activity/selectivity observed with CCCP and diarylacylhydrazones implies that a protonophoric mechanism probably plays some role in the mechanism. That CCCP and diarylacylhydrazones both carry hydrazone moieties may be important but this remains to be determined.
MIC ( g/mL)
C Given the known effects of CCCP as a protonophoric uncoupler of oxidative phosphorylation, 28 it was of interest to examine human cell cytotoxicity as a preliminary indicator of druggability (or otherwise) in the diarylacylhydrazone class. Compounds 5 and 6 were examined alongside miconazole (positive control), metronidazole 1, vancomycin 2 and CCCP for cytotoxicity against human FaDu and Hep G2 cells using a standard 96-well resazurin-based cell viability assay (Supporting Information).
The positive control miconazole showed the expected cytotoxic concentration (50 g/mL) against both cell lines. Metronidazole 1 and vancomycin 2 showed no toxicity at or below 200 g/mL against either cell line. Compounds 5 and 6 showed no cytotoxicity against either cell line at 100 g/mLwhile CCCP was found to be toxic at 50 g/mL ( Figure 6 ). 
